Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model

Charles H. Lineweaver, Paul Davies, Mark D. Vincent

Research output: Contribution to journalArticle

19 Scopus citations

Abstract

In the atavistic model of cancer progression, tumor cell dedifferentiation is interpreted as a reversion to phylogenetically earlier capabilities. The more recently evolved capabilities are compromised first during cancer progression. This suggests a therapeutic strategy for targeting cancer: design challenges to cancer that can only be met by the recently evolved capabilities no longer functional in cancer cells. We describe several examples of this target-the-weakness strategy. Our most detailed example involves the immune system. The absence of adaptive immunity in immunosuppressed tumor environments is an irreversible weakness of cancer that can be exploited by creating a challenge that only the presence of adaptive immunity can meet. This leaves tumor cells more vulnerable than healthy tissue to pathogenic attack. Such a target-the-weakness therapeutic strategy has broad applications, and contrasts with current therapies that target the main strength of cancer: cell proliferation.

Original languageEnglish (US)
Pages (from-to)827-835
Number of pages9
JournalBioEssays
Volume36
Issue number9
DOIs
StatePublished - Sep 2014

Keywords

  • Adaptive immunity
  • Cancer therapy
  • Carcinogenesis
  • Evolution of multicellularity

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model'. Together they form a unique fingerprint.

  • Cite this